Eli Lilly (NYSE:LLY) secured Medicare coverage for Zepbound and Foundayo through a GLP‑1 Bridge program from July 1 to Dec 2027 with a $50 copay, boosting sales potential as FDA PreCheck for its Lebanon plant aids supply — though uptake, rollout, prior auth and short program duration pose risks.
Previous Week Recap
- Medicare Covers Zepbound, Foundayo: Medicare will cover Eli Lilly’s obesity drugs Zepbound and Foundayo in a GLP‑1 Bridge program from July 1 through Dec 2027; $50 monthly copay, requires prescription, prior authorization and Part D.
- Bridge Program Boosts Lilly Sales: Analysts say Lilly’s Bridge program could boost global sales materially; actual impact for Eli Lilly depends on rollout, patient uptake, private insurance response and long-term coverage dynamics.
- Lilly Plant Joins FDA PreCheck: FDA added Eli Lilly’s Lebanon, IN plant—maker of active ingredients for its weight‑loss drugs—to the PreCheck pilot, enabling early regulatory review of design, construction and quality readiness.
- Lilly Obesity Program Risks: Eli Lilly (LLY) faces implementation risks for its obesity treatment program through 2027: slow approvals, prior-authorization hurdles, limited pharmacy supply, and the program's temporary duration.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.